Pfizer’s Arms-Length Attitude Toward Operation Warp Speed: Two Views On How It Worked
Pfizer CEO Albert Bourla and HHS deputy chief of staff Paul Mango offer their perspectives in separate interviews promoting new books about the campaign to develop vaccines against COVID-19.
You may also be interested in...
CBER’s Marks said US FDA is working with Novavax on manufacturing to allow its protein-based vaccine to be ready for a fall roll-out. After some concerns about international coordination, multiple regulators seem to be settling on a monovalent approach for fall vaccinations.
The company could reach $100bn in revenues in 2022 for the first time, powered by Comirnaty and Paxlovid; actual sales for the COVID-19 products are likely to go higher based on supply contracts.
Government offers help securing supplies in return for another 100 million doses by Q2. That would mean abandoning Pfizer’s preferred arms-length relationship.